The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

ASCO: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-free survival for early-stage colon cancer

Bookmark and Share

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Please rate this video

The information in this video was of interest to me

The information in this video is likely to improve my clinical practice or research

I would recommend this video to my colleagues
Published: 17 Jun 2009
Views: 13076
Rating:
Save
Dr Norman Wolmark - Chairman Dept of Human Oncology, Allegheny General Hospital, US
ASCO press conference: Adding bevacizumab (avastin) to standard adjuvant chemotherapy does not improve disease-free survival for early-stage colon cancer

Related Videos

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with ...
Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation ( Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA )
20 Sep 2021
Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) w...
Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China
Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) with Capecitabine for patients with LARC ( Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China )
20 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 4
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 4 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
20 Sep 2021
FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-l...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-line treatment of unresectable mCRC patients ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
18 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )
17 Sep 2021
Oesophageal and gastric cancers
Dr Mike Cusnir - Mount Sinai Medical Center, Florida, USA
Oesophageal and gastric cancers ( Dr Mike Cusnir - Mount Sinai Medical Center, Florida, USA )
28 Jul 2021
BEACON-CRC: first-line bevacizumab in colorectal cancer treatment
Prof Dan Aderka - Tel-Aviv University, Tel-Aviv, Israel
BEACON-CRC: first-line bevacizumab in colorectal cancer treatment ( Prof Dan Aderka - Tel-Aviv University, Tel-Aviv, Israel )
26 Jul 2021
OncoAlert and ecancer weekly round up for July 12- July 18, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for July 12- July 18, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
19 Jul 2021
Cell free DNA BRAF mutant allele fraction and whole exome sequencing in BRAFV600...
Dr Elena Elez - Vall d'Hebron University Hospital, Barcelona, Spain
Cell free DNA BRAF mutant allele fraction and whole exome sequencing in BRAFV600E metastatic colorectal cancer ( Dr Elena Elez - Vall d'Hebron University Hospital, Barcelona, Spain )
13 Jul 2021

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation